These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 19027590)

  • 1. Myotoxicity of lipid-lowering agents in a teenager with MELAS mutation.
    Tay SK; Dimauro S; Pang AY; Lai PS; Yap HK
    Pediatr Neurol; 2008 Dec; 39(6):426-8. PubMed ID: 19027590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myotoxicity associated with lipid-lowering drugs.
    Baer AN; Wortmann RL
    Curr Opin Rheumatol; 2007 Jan; 19(1):67-73. PubMed ID: 17143099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of A3243G point mutation in mitochondrial DNA from 10 cases of MELAS.
    Wang Z; Liu S; Yang Y; Yuan Y; Wu L; Qi Y; Chen Q
    Chin Med J (Engl); 2002 Jul; 115(7):995-7. PubMed ID: 12150728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An infant with a mitochondrial A3243G mutation demonstrating the MELAS phenotype.
    Kanaumi T; Hirose S; Goto Y; Naitou E; Mitsudome A
    Pediatr Neurol; 2006 Mar; 34(3):235-8. PubMed ID: 16504796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin-associated myopathy with normal creatine kinase levels. Case report from a Norwegian family.
    Trøseid M; Henriksen OA; Lindal S
    APMIS; 2005 Sep; 113(9):635-7. PubMed ID: 16218940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different effects of novel mtDNA G3242A and G3244A base changes adjacent to a common A3243G mutation in patients with mitochondrial disorders.
    Mimaki M; Hatakeyama H; Ichiyama T; Isumi H; Furukawa S; Akasaka M; Kamei A; Komaki H; Nishino I; Nonaka I; Goto Y
    Mitochondrion; 2009 Apr; 9(2):115-22. PubMed ID: 19460299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nerve conduction abnormalities in patients with MELAS and the A3243G mutation.
    Kaufmann P; Pascual JM; Anziska Y; Gooch CL; Engelstad K; Jhung S; DiMauro S; De Vivo DC
    Arch Neurol; 2006 May; 63(5):746-8. PubMed ID: 16682545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Identification of an ideal noninvasive method to detect A3243G gene mutation in MELAS syndrome].
    Ma YN; Fang F; Yang YL; Zhang Y; Wang ST; Xu YF; Pei P; Yuan Y; Bu DF; Qi Y
    Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(46):3250-3. PubMed ID: 19159547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A mitochondrial DNA mutation in a patient with an extensive family history of Duchenne muscular dystrophy.
    Wong LJ; Wladyka C; Mardach-Verdon R
    Muscle Nerve; 2004 Jul; 30(1):118-22. PubMed ID: 15221888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS) with the A3243G mutation of the tRNALeu(UUR) gene of mtDNA in native American haplogroup B2].
    Delgado-Sánchez R; Zárate-Moysen A; Monsalvo-Reyes A; Herrero MD; Ruiz-Pesini E; López-Pérez M; Montoya J; Montiel-Sosa JF
    Rev Neurol; 2007 Jan 1-15; 44(1):18-22. PubMed ID: 17199225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of complex I genes in MELAS: a novel heteroplasmic mutation 3380G>A in ND1 of mtDNA.
    Horváth R; Reilmann R; Holinski-Feder E; Ringelstein EB; Klopstock T
    Neuromuscul Disord; 2008 Jul; 18(7):553-6. PubMed ID: 18590963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis.
    Harper CR; Jacobson TA
    Curr Opin Lipidol; 2007 Aug; 18(4):401-8. PubMed ID: 17620856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Muscle 3243A-->G mutation load and capacity of the mitochondrial energy-generating system.
    Janssen AJ; Schuelke M; Smeitink JA; Trijbels FJ; Sengers RC; Lucke B; Wintjes LT; Morava E; van Engelen BG; Smits BW; Hol FA; Siers MH; Ter Laak H; van der Knaap MS; Van Spronsen FJ; Rodenburg RJ; van den Heuvel LP
    Ann Neurol; 2008 Apr; 63(4):473-81. PubMed ID: 18306232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of the MELAS m.3243A>G mutation with myositis and the superiority of urine over muscle, blood and hair for mutation detection.
    Marotta R; Reardon K; McKelvie PA; Chiotis M; Chin J; Cook M; Collins SJ
    J Clin Neurosci; 2009 Sep; 16(9):1223-5. PubMed ID: 19502062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wolff-Parkinson-White syndrome in Patients With MELAS.
    Sproule DM; Kaufmann P; Engelstad K; Starc TJ; Hordof AJ; De Vivo DC
    Arch Neurol; 2007 Nov; 64(11):1625-7. PubMed ID: 17998445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MELAS A3243G mitochondrial DNA mutation and age related maculopathy.
    Jones M; Mitchell P; Wang JJ; Sue C
    Am J Ophthalmol; 2004 Dec; 138(6):1051-3. PubMed ID: 15629304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of systemic redox states in patients carrying the MELAS A3243G mutation in mitochondrial DNA.
    Ikawa M; Arakawa K; Hamano T; Nagata M; Nakamoto Y; Kuriyama M; Koga Y; Yoneda M
    Eur Neurol; 2012; 67(4):232-7. PubMed ID: 22517274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statin myopathy as a metabolic muscle disease.
    Phillips PS; Haas RH
    Expert Rev Cardiovasc Ther; 2008 Aug; 6(7):971-8. PubMed ID: 18666847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain single photon emission computed tomography in patients with A3243G mutation in mitochondrial DNA tRNA.
    Thajeb P; Wu MC; Shih BF; Tzen CY; Chiang MF; Yuan RY
    Ann N Y Acad Sci; 2005 May; 1042():48-54. PubMed ID: 15965044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Statins and muscular side-effects].
    Brosteaux C; Ruiz J; Buclin T; Kuntzer T; Rodondi N
    Rev Med Suisse; 2010 Mar; 6(239):510, 512-4, 516-7. PubMed ID: 20373698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.